Trial Profile
Bioequivalence Study of the Fixed Dose Combination of 5 mg Saxagliptin/1000 mg Metformin XR (Manufactured in Mt Vernon, IN) Relative to 5 mg of Onglyza and 2 x 500 mg Glucophage XR Coadministered to Healthy Subjects in the Fed State and Steady State Pharmacokinetic Assessment of the Fixed Dose Combination of 5 mg Saxagliptin/1000 mg Metformin XR
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Saxagliptin/metformin (Primary) ; Metformin; Saxagliptin
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 08 Nov 2010 Extended-release saxagliptin/metformin [KOMBIGLYZE XR] has received FDA approval for the treatment of type 2 diabetes mellitus, according to a Bristol-Myers Squibb media release.
- 09 Sep 2010 New trial record